Multiple Myeloma | Specialty

The OncLive Multiple Myeloma condition center page is a comprehensive resource for clinical news and expert insights on multiple myeloma and how to treat patients with monoclonal antibodies, proteasome inhibitors, bispecific T-cell engagers, immunomodulatory agents, CAR T-cell therapy, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in multiple myeloma.

Dr Lonial on Findings from the CoMMpass Trial in Multiple Myeloma

September 6th 2024

Sagar Lonial, MD, FACP, discusses findings from the CoMMpass trial, which identified high-risk genetic markers in patients with myeloma.

D-VRd Improves MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Myeloma

September 6th 2024

D-VRd improved rates of MRD negativity and sustained MRD negativity vs VRd in transplant-eligible, newly diagnosed multiple myeloma.

FDA Approves Bortezomib Injectable for Multiple Myeloma and MCL

September 6th 2024

The FDA has approved a new presentation of bortezomib for subcutaneous or intravenous administration.

Clinical Insights on the Patient Presentation & Treatment Course

September 4th 2024

The panel shares their expert impressions of the case and deliberates on potential treatment strategies for the 53-year-old patient with heavily pre-treated multiple myeloma, considering his prior therapies and current clinical status.

Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

September 4th 2024

The panel presents and analyzes a case study of a 53-year-old man with heavily pre-treated multiple myeloma, including chemotherapy – based therapy and prior T-cell directed therapy, to illustrate treatment considerations and challenges in advanced disease management.

Dr Arnulf on Managing Tumor Burden for Improved PFS With Ide-Cel in R/R Myeloma

September 4th 2024

Bertrand Arnulf, MD, PhD, discusses the importance of managing tumor burden for improved outcomes with ide-cel in relapsed/refractory multiple myeloma.

Growth in the Multiple Myeloma Treatment Armamentarium Diversifies Treatment Strategies

September 2nd 2024

Rahul Banerjee MD, FACP, discusses how he decides between treatment approaches across subsets of patients with multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 8/25

August 31st 2024

Mirdametinib NDA gets priority review in NF1-associated plexiform neurofibromas, experts explore social media's evolving role in cancer care, and more.

Dr McCarthy on Neutrophil Activity in Multiple Myeloma

August 30th 2024

Philip McCarthy, MD, discusses a study of neutrophil gene signatures within focal lesions that are linked to progression-free survival in multiple myeloma.

Stepwise Approach Helps Ease the Integration of BiTEs Into Community Cancer Centers

August 29th 2024

Courtney Van Houzen, PharmD, discusses key factors to be aware of when implementing bispecific T-cell engager programs into the community setting.

Dr Krishnan on Maintenance Approaches in Transplant-Ineligible Multiple Myeloma

August 29th 2024

Amrita Krishnan, MD, discusses maintenance therapy for patients with transplant-ineligible, newly diagnosed multiple myeloma.

Dr Banerjee on Various Dosing Schedules of Bispecific Antibodies in Myeloma

August 29th 2024

Rahul Banerjee, MD, FACP, discusses the ongoing investigation into different dosing schedules of bispecific antibodies in multiple myeloma.

Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

August 28th 2024

The panel evaluates selinexor's current role in the treatment landscape for multiple myeloma and explores its potential future applications and evolving significance in therapeutic strategies.

Overview of CAR T-cell Therapy Options in R/R MM

August 28th 2024

The experts examine the available CAR T-cell therapy options for relapsed/refractory multiple myeloma.

Bispecific Antibody De-Escalation: Varying Dosing Strategies Aim to Improve Safety, Maintain Efficacy in R/R Myeloma

August 27th 2024

Rahul Banerjee MD, FACP, discusses various dosing strategies and schedules for bispecific antibodies in multiple myeloma.

Dr Sonneveld on the Background of the D-VRd Regimen in Newly Diagnosed Myeloma

August 27th 2024

Pieter Sonneveld, MD, PhD, discusses the background of the PERSEUS trial, which evaluated D-VRd for induction and consolidation in newly diagnosed myeloma.

Time-Limited Bispecific Antibodies Could Represent Next Shift in Myeloma Treatment

August 26th 2024

Rahul Banerjee MD, FACP, discusses the rapidly evolving therapeutic landscape of bispecific antibodies in the treatment of patients with multiple myeloma.

DREAMM-7 and DREAMM-8 Data Support Belantamab Mafodotin–Based Combos in R/R Myeloma

August 24th 2024

Suzanne Trudel, MSc, MD, discusses updated data from the DREAMM-7 and DREAMM-8 trials of belantamab mafodotin–based regimens in R/R multiple myeloma.

The OncFive: Top Oncology Articles for the Week of 8/18

August 24th 2024

A frontline doublet receives FDA approval in EGFR+ NSCLC, a CRL is issued to linvoseltamab in multiple myeloma, and more this week from OncLive.

Dr Krishnan on the Role of Cilta-Cel in High-Risk Multiple Myeloma

August 23rd 2024

Amrita Krishnan, MD, discusses the potential role for cilta-cel in early-relapsed, high-risk patients with multiple myeloma.